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Abstract
Like natural viruses, manmade protein cages for drug delivery are to be ideally formed by repetitive subunits with
self-assembling properties, mimicking viral functions and molecular organization. Naturally formed nanostructures
(such as viruses, flagella or simpler protein oligomers) can be engineered to acquire specific traits of interest in
biomedicine, for instance through the addition of cell targeting agents for desired biodistribution and specific
delivery of associated drugs. However, fully artificial constructs would be highly desirable regarding finest tuning
and adaptation to precise therapeutic purposes. Although engineering of protein assembling is still in its infancy,
arising principles and promising strategies of protein manipulation point out the rational construction of nanoscale
protein cages as a feasible concept, reachable through conventional recombinant DNA technologies and microbial
protein production.
Commentary
Targeted drug and nucleic acid delivery, in which bio-
distribution is achieved by ligand-receptor interactions,
is a promising way to reduce drug toxicity and enhance
effectiveness, what is of special relevance for the treat-
ment of cancer and chronic viral diseases, among others.
In gene therapy, the term ‘artificial viruses’ has been
proposed to describe virus-like constructs exhibiting
specific viral functions that are relevant to cell recogni-
tion, penetration and compartment-aimed release of
cargo nucleic acids [1-3]. This nanoparticle-based con-
cept, which can be also extended to chemical drug deliv-
ery, involves the use of refillable cages and the
incorporation of functional agents for cell receptor bind-
ing, cellular uptake and eventually endosomal escape
and nuclear delivery. Lipidic and polymeric nanoparti-
cles have been under continuous development during
the last four decades [4-6], while nanofibers, nanowires,
carbon nanotubes and other types of nanosized cages
are being progressively incorporated into the drug deliv-
ery scenario [7]. The desired molecular organization,
size dispersion and geometry of these constructs is
achieved by mechanical and chemical approaches,
through fine micro- or nanofabrication procedures [8,9].
Most of these particles are blind; therefore they require
to be functionalized with targeting agents for specific
cell attachment, being proteins the most efficient, versa-
tile and tunable tools for cell and tissue targeting.
Advances in proteomics and systems biology have per-
mitted to expand the existing catalogues of molecular
markers relevant in biomedicine, specially those of inter-
est in cancer diagnosis and therapy [10-14]. In parallel,
growing numbers of peptides, antibodies and other pro-
tein ligands suitable for cell targeted delivery are becom-
ing available [15-25], supported by the efforts in
medical-focused applications of peptide display technol-
ogies [20,26-29]. All these findings provide a growing
spectrum of therapeutic opportunities in the context of
innovative and personalized medicines.
Interestingly, protein-only entities are appealing candi-
dates as building blocks of drug delivery cages [30,31].
Their biocompatibility, biological fabrication, functional
diversity and versatility of design though protein engi-
neering (assisted by in silico instruments) make them
extremely plastic and powerful materials in comparison
with liposomes and other types of artificial viruses.
Importantly, modular approaches to protein engineering
permit the accommodation of several virus-like func-
tions in single (hybrid) polypeptide chains [16,25,32]. In
addition, since many microbial and non microbial
organisms are being used as cell factories for therapeutic
proteins [33], a wide spectrum of biological platforms,
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production strategies is available [34]. In particular, bac-
terial cells are generically good producers of diverse
nanomaterials of medical application, including poly-
mers, metal particles and protein particles [35].
The microbial production of protein particles of bio-
medical interest has been mainly focused on bacterio-
phages for peptide display, virus-like particles as
immunogens and flagella and filamentous phages as
templates for micro- and nanofabrication [35,36]. Apart
from peptide-displaying filamentous phages, which have
been widely explored for targeted delivery of DNA and
conjugated drugs in cell culture but also in vivo [37-39],
these particles have been in general hardly adaptable to
cell-targeted drug delivery.
Ideally, polypeptides with specific functions relevant to
drug delivery (mimicking those of viruses, [16]), should
be engineered to self-assemble as nanoparticles with
desired nanoscale properties, namely size and geometry,
and produced in simple heterologous hosts. The con-
struction of protein particles from their building blocks,
as it occurs in natural viruses, can not be achieved by
conventional nano-fabrication but through the selection
of protein sequences promoting regular protein-protein
interactions in absence of unspecific aggregation. In this
regard, sets of both natural and non-natural amino acid
sequences have been identified that promote peptide
self-assembling in diverse patterns. Among them hydro-
gels, bilayers and nanofibers show important applica-
tions in tissue engineering but also in drug delivery
[40-44]. Peptide self-assembling can be eventually con-
trolled by pH, temperature and other environment para-
meters [45-47], and it often involves the formation of
amyloid-like, beta-sheet cross-molecular interactions
[41] similar to those governing the formation of bacter-
ial inclusion bodies [48-51]. Amyloid-like architecture is
probable driving also the assembling of protein fibers
formed by misfolding prone recombinant proteins in the
cytoplasm of recombinant bacteria [52,53]. Interestingly,
some of these short peptides have been successfully pro-
duced in bacteria by means of conventional recombinant
DNA approaches, fused to carrier proteins or as tandem
repeats to enhance their stability [44,54-56] (Figure 1).
Very few of these peptides have been yet incorporated
to larger, modular protein constructs for drug delivery
to form multifunctional, virus-like protein cages. How-
ever, a couple of examples from our own experience
prove the feasibility of the concept. In this regard, poly-
lysine stretches, commonly used as cationic peptides for
DNA condensation [57], confer architectonic properties
to engineered beta-galactodidases, which already con-
tained several functional motives for cell receptor bind-
ing and nuclear delivery. These chimerical enzymes
formed amorphous nanoparticles [58,59], and have been
proved to be excellent artificial viruses for in vivo gene
delivery to the nervous system in ischemia models and
for both histological and functional recovery of injured
animals [60,61]. Also, poly-arginine peptides, again used
by their DNA condensation properties promoted the
self-assembling of scaffold green fluorescent proteins as
monodisperse, highly regular 20 nm-nanoparticles useful
for DNA and protein delivery [62]. These particles are
formed irrespective of the solubility exhibited by the
protein under different storage conditions [62,63], prov-
ing high regularity and consistence in their architectonic
schemes. Interestingly, once exposure to cultured mam-
malian cells, the intracellular trafficking of these entities
is extremely efficient, showing a fast and steady nuclear
accumulation in fluorescent forms [62,64]. The sticky
nature of cationic peptides, although not completely
solved, does not seem to involve cross beta-sheet
interactions.
These last results provide a valid proof of concept of
the incorporation of self-assembling peptides to complex
protein building blocks of artificial viruses (Figure 1),
although this is still far from rational design. Moreover,
steady conceptual advances in the biology of protein-
protein interactions and the easy bioproduction of chi-
merical proteins in microbial hosts, permit to envisage
further progresses in the design of protein cages for
drug delivery based on both protein engineering and the
exploitation of microbial cell factories.
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